Merck & Co's (NYSE:MRK) stock is 22.8% higher in the past 12 months and has outperformed the overall US TECH market which is 3.9% higher in the same timeframe. This equates to a 18.9% greater return over the period which puts the stock as an outperformer vs other US TECH companies.
From 21 analysts that cover Merck & Co's stock, the average rating is 3.7. This is a weighted average of 4 strong buys, 7 buys, 10 holds. This is 0.5 lower than a month ago which gives this factor a tea-score of 1/5.
Merck & Co insider's have net been buying stock over the past 12 months, in the previous month insiders have been net buying. In fact the buy to sell ratio in the past month has been 50.0% which is 49.0% higher than the last 12 months buy to sell ratio. This put's Merck & Co's Insiders in the top quintile vs their peers giving this factor a tea-score of 1/5.
For Merck & Co, currently 78.3% of stock (1 billion shares) is owned by Institutions, 21.6% (802 million shares) is owned by Individuals, and 0.1% (2 million shares) is owned by company insiders. The CEO has a holding of 0.02% which is equivalent to 40 thousand shares with a market value of $129 million. This factor has a tea-score of 4/5.
As of 31 July 2019, the short interest for Merck & Co has been 0.73% of the shares outstanding which is 189 billion shares. This is less than 1 month ago which had 0.76% of the shares outstanding which is 194 billion short interest in shares. This equals a tea-score of 5/5.
Merck & Co's revenue in the last 12 months ending 30 June 2019 is $44Bn. Merck & Co's average revenue growth for the last 4 years has been 5.1% which is currently lower than their comps of 6.2%.
Merck & Co's free cash flow yield is 4.3% and has shrunk from 4 years ago. The free cash flow yield for Merck & Co 1 year ago was 3.3% and 3 years ago it was 9.2%.
Merck & Co pays dividends every 3 months and has done so since 02 April 2013. Dividends have been steadily increasing over the past 4 years from $0.45 (dividend yield of 0.97%) to $0.55 today (yield of 0.66%).
Merck & Co's PE ratio is 23.9x. This is calculated from their EPS of $2.02 and price per share of $84.35. Merck & Co's PE ratio values the company cheaper than 60% of it's competitors giving this factor a tea-score of 3/5.
Merck & Co's PEG ratio is 0.4x. This is calculated from their PE ratio of 23.9x and their last 12 months growth rate of 0.564%. This is more attractive than their competitors so the tea-score for this factor is 2/5.
The PB ratio for Merck & Co is 7.9x. This is more expensive than their competitors who have an average PB ratio of 3.8x. The tea-score is 5/5.
Merck & Co's free cash flow yield is 4.3% which is ranked 2.0/5 when compared to its competitors. This is calculated from a free cash flow of - (as reported for the 12 months ending 30 June 2019) divided by its current market capitalisation of $217Bn. The average free cash flow yield across Merck & Co's comps is 8.1%.
Merck & Co's return on investment is 30.6%. This is more profitable than its competitors.
Merck & Co's current ratio is calculated by (current assets) / (current liabilities) which equals 1.2x. This less attractive than their competitors and also worse than recommended for a healthy company.
Merck & Co's debt to shareholder equity is 99.5%. This is worse than their competitors and also worse than advised for a well-managed balance sheet.
Merck & Co's dividend payout ratio calculated against their free cash flow is low at 55.1%. This is in quintile 3 when measured against their comps.
Merck & Co's has a good overall ESG rating of 68/100. Their competitors have a score between 38 and 79 with the average at 58.
What is the 52 week high for Merck & Co stock quote?
Merck & Co (NYSE:MRK) hit a new 52-week high on 03 July 2019 at a price of $86.9 with 6,234,000 shares traded that day. This is 3.0% higher than than its current price of $84.35 and 31.4% higher than the 52-week low of $66.13 on 04 September 2018. Average daily volume traded has been 10 million shares over the past 3 months.
What is the highest price Merck & Co stock has ever been?
The all-time highs for Merck & Co stock were reached on 03 July 2019, 47 days ago at a price of $86.9. This equates to a market capitalisation of $223Bn. The highest price reached is 3.0% higher than the current price of $84.35 with a current market cap of $217Bn.
What is the beta of Merck & Co stock?
Merck & Co stock moves 0.3x the US TECH market average which makes its beta higher than the overall market.
What is the volatility of Merck & Co (MRK) stock?
Merck & Co's stock has an annual volatility of 18.6% which is more volatile than the average US TECH market volatility of 16.3% which has made it a less safe stock to own in the past vs just owning the index for investors aiming for lower portfolio volatility.
What have Merck & Co's share buybacks been over the past year?
Merck & Co is currently running a share-buyback program and in the past year alone the company has repurchased 104 million of shares outstanding at a total expense of $23Trn. In the same time frame the share price has moved 22.8% higher which is an outperformance of 18.9% vs the overall market. Merck & Co still has $420Trn of cash remaining on their balance sheet.
Who owns the most Merck & Co stock?
Barry White is the largest individual shareholder in Merck & Co with 1 billion shares. He is an independent director of Merck & Co. The largest institutional holder is T-Rowe and they own 3.9% of the issue size with 100 million shares. T-Rowe have been net buying shares over the last 12 months as they own 1 million more shares than a year ago.
When did Merck & Co beat earnings expectations in the last 4 years?
In the past 4 quarters Merck & Co has had 3 earnings beat's and 1 earnings miss's. The average earnings beat has been 12.1% and the average earnings miss has been 8.2%.
When is Merck & Co's next earnings date and what are the expectations?
Merck & Co is set to report earnings on 30 July 2019 after market close. The report will be for the fiscal Quarter ending June 2019. Based on 14 analysts' forecasts, the consensus EPS forecast for the quarter is $2.12. Recent analyst revisions have been positive implying a potential EPS of $2.24.
What is Merck & Co's upcoming earnings report expectations?
The earnings expectations for Merck & Co's upcoming report on 30 July 2019 are from 14 analysts with an average EPS of $2.12. The lowest analyst rating is $2.01, the highest is $2.84. The most recent earnings revisions have been positive with a most recent estimate of $2.24.
What is Merck & Co's earnings per share (EPS)?
Merck & Co's latest earnings per share (EPS) was reported as $2.02 on 30 April 2019 for fiscal quarter ending March 2019. This is 11.0% higher than 12 months ago when they reported EPS of $1.82
What is Merck & Co's dividend growth rate?
Merck & Co's dividends have grown at 14.58% in the past year and an average growth of 5.56% over the past 4 years. This is higher then it's competitors 4-year average dividend growth of 4.1
What is Merck & Co's dividend yield?
Merck & Co's current dividend yield is 0.66%. This is calculated by taking the dividend's per share of $0.55 (the last payment which was on 14 June 2019) and dividing by the current share price of $84.35.
What is Merck & Co's previous and next dividend date?
Merck & Co's most recent dividend date was 14 June 2019 when the company paid $0.55 and the next dividend date is 14 September 2019 with an expected payment of $0.55.